艾多沙班与华法林在房颤合并肝病史患者中的比较
ENGAGE AF-TIMI 48 随机双盲试验事后分析,比较艾多沙班与华法林在房颤合并肝病史患者中的药代/药效及临床结局;肝病史患者大出血风险更高,但艾多沙班相对华法林的疗效与安全性不受肝病史影响,肝脏不良事件两组相似。
要点
- 房颤合并肝病史患者大出血风险较无肝病史者更高。
- 艾多沙班相对华法林的疗效与安全性不受肝病史影响。
- 肝病史患者中艾多沙班与华法林的肝脏不良事件无显著差异。
核心结论
- 在口服抗凝的房颤患者中,肝病史与大出血风险增加相关,但未增加血栓栓塞事件。
- 肝病史不改变艾多沙班相对华法林的疗效与安全性。
研究设计与样本
- ENGAGE AF-TIMI 48 为随机双盲试验,比较艾多沙班与华法林治疗房颤患者并随访 2.8 年。
- 肝病史定义为研究者报告的肝病或随机化时转氨酶升高超过 2 倍。
主要发现
- 21,105 例患者中 1,083 例(5.1%)有肝病史,合并症患病率更高。
- 肝病史患者校正后 SSEE 风险相似(HRadj 0.90;95%CI 0.67–1.22;p=0.50),但大出血更常见(HRadj 1.38;95%CI 1.10–1.74;p=0.005)。
- 艾多沙班的 PK/PD 评估在有无肝病患者间无显著差异。
- 高剂量艾多沙班 vs 华法林:无肝病者 SSEE HR 0.86(95%CI 0.73–1.01),肝病者 1.11(95%CI 0.54–2.30),pint=0.47;大出血无肝病者 HR 0.80(95%CI 0.70–0.91),肝病者 0.91(95%CI 0.56–1.47),pint=0.63。
- 两治疗组肝脏不良事件无显著差异。
临床怎么用
- 房颤合并肝病史患者使用口服抗凝药时应关注出血风险。
- 艾多沙班可用于房颤合并肝病史患者,其相对疗效与安全性与无肝病史者相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with liver disease have increased risk of thrombosis and bleeding but are typically excluded from trials of direct oral anticoagulant agents. OBJECTIVES: This study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), clinical efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation (AF) and history of liver disease. METHODS: ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction Study 48) was a randomized, double-blind trial comparing edoxaban with warfarin in patients with AF followed for 2.8 years. History of liver disease was defined as investigator-reported liver disease or >2-fold transaminase elevation at randomization. The primary efficacy and safety endpoints of stroke or systemic embolic event (SSEE) and major bleeding were assessed stratified by history of liver disease. PK/PD assessments of edoxaban included endogenous and extrinsic factor Xa activity and edoxaban concentration. RESULTS: Among 21,105 patients, 1,083 (5.1%) had a history of liver disease; they had a higher prevalence of many comorbidities. The adjusted risks of SSEE were similar (adjusted hazard ratio [HRadj]: 0.90; 95% confidence interval [CI]: 0.67 to 1.22; p = 0.50), but major bleeding was more common in patients with liver disease (HRadj: 1.38; 95% CI: 1.10 to 1.74; p = 0.005). There were no significant differences in PK/PD assessment of edoxaban in patients with versus without liver disease. The HRs for higher-dose edoxaban versus warfarin for SSEE were 0.86 (95% CI: 0.73 to 1.01) in patients without and 1.11 (95% CI: 0.54 to 2.30) with liver disease (p for interaction [pint] = 0.47), major bleeding 0.80 (95% CI: 0.70 to 0.91) in patients without and 0.91 (95% CI: 0.56 to 1.47) with liver disease (pint = 0.63). There were no significant differences in hepatic adverse events between the 2 treatment groups. CONCLUSIONS: Among patients with AF receiving oral anticoagulation, bleeding, but not thromboembolic events, was increased in patients with liver disease. A history of liver disease did not alter the relative efficacy and safety of edoxaban compared with warfarin. Hepatic adverse events were similar between edoxaban and warfarin.
引用
- Qamar A, Antman EM, Ruff CT, et al. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. J Am Coll Cardiol. 2019. PMID: 31296289. doi:10.1016/j.jacc.2019.04.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。